Successful treatment of pulmonary mucormycosis in an allogenic bone-marrow transplant recipient with combined medical and surgical therapy

Scandinavian Journal of Infectious Diseases

Volumn 36, Issue 10, 2004, Pages 767-769

  Pavie, Juliette ^a   Lafaurie, Matthieu ^a   Lacroix, Claire ^b   Zagdanski, Anne Marie ^b   Debrosse, Denis ^c   Socié, Gérard ^b   Derouin, Francis ^b   Gluckman, Eliane ^b   Molina, Jean Michel ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c INSTITUT MUTUALISTE MONTSOURIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTINEOPLASTIC AGENT; CD20 ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; FLUDARABINE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIPERACILLIN PLUS TAZOBACTAM; STEROID; THYMOCYTE ANTIBODY;

ADOPTIVE IMMUNOTHERAPY; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLOOD CULTURE; CANCER RECURRENCE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DRUG WITHDRAWAL; ESCHERICHIA COLI; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; HLA MATCHING; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LUNG MYCOSIS; MALE; MORTALITY; MOULD; MUCORALES; MUCORMYCOSIS; NONHODGKIN LYMPHOMA; NOSE INFECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; RECIPIENT; SPUTUM ANALYSIS; TREATMENT OUTCOME;

EID: 7944229735     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365540410021081a     Document Type: Article

References (11)

1. Morrison VA, McGlave PB. BMucormycosis in the BMT population. Bone Marrow Transplant 1993; 11: 383-8.
2. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in haematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-17.
3. Maertens J, Demuynck H, Verbeken EK, Zachee P, Verhoef G, Vandenberghe P, Boogaerts MA. Mucormycosis in allogenic bone marrow transplantation: report of 5 cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant 1999; 24: 307-12.
4. Tedder M, Spratt JA, Anstadt MP, Hedge SS, Tedder SD, Lowe JE. Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg 1994; 57: 1044-50.
5. Lee FYW, Mossad SB, Adal KA. Pulmonary mucormycosis. Arch Int Med 1999; 159: 1301-9.
6. Bigby TD, Serota ML, Tierney LM, Matthay MA. Clinical spectrum of pulmonary mucormycosis. Chest 1986; 89: 435-9.
7. McAdams HP, Rosado de Christenson M, Strollo DC, Patz EF Jr. Pulmonary mucormycosis: radiological findings in 32 cases. Am J Roentgenol 1997; 168: 1541-8.
8. Ascioglu S, Rex JH, de Paws B, Benett JE, Bille J, Crokaert F, et al. Defining opportunistic invasive fungal infections in immunocompromized patients with cancer and haematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
9. Herbrecht R, Denning DW, Patterson TF, Benett JE, Greene RE, Oestmann JW, et al. Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer, and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
10. Gome-Lopez A, Cuenca-Estrella M, Monzon A, Rodriguez-Tudela JL. In vitro susceptibility of clinical isolates of Zygomycota to amphotericin B, flucytosine, itraconazole and voriconazole. J Antimicrob Chem 2001; 48: 919-21.
11. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of haematopoietic stem cell transplants. N Engl J Med 2004; 350: 950-2.